Bionomics, Deborah Rathjen: Developing a world-class portfolio of promising drug candidates




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Bionomics, Deborah Rathjen: Developing a world-class portfolio of promising drug candidates
Released on: January 09, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this interview filmed at the 2013 AusBiotech Convention in Brisbane,Deborah Rathjen, CEO, Bionomics updates Fintan Walton on the company activities over the last 12 months, including their deal with Merck & Co and explains why they are are in a strong growth phase with a world-class portfolio of promising drug candidates from early to advanced stages of clinical development.
  • Summary
  • Transcript
  • Participants
  • Company
In this interview filmed at the 2013 AusBiotech Convention in Brisbane,Deborah Rathjen, CEO, Bionomics updates Fintan Walton on the company activities over the last 12 months, including their deal with Merck & Co and explains why they are are in a strong growth phase with a world-class portfolio of promising drug candidates from early to advanced stages of clinical development. This portfolio is fed by highly productive drug discovery platforms which includes MultiCore®, their proprietary chemistry capability.
In this interview filmed at the 2013 AusBiotech Convention in Brisbane,Deborah Rathjen, CEO, Bionomics updates Fintan Walton on the company activities over the last 12 months, including their deal with Merck & Co and explains why they are are in a strong growth phase with a world-class portfolio of promising drug candidates from early to advanced stages of clinical development. This portfolio is fed by highly productive drug discovery platforms which includes MultiCore®, their proprietary chemistry capability.
Deborah Rathjen
Bionomics
Bionomics
Bionomics is a productive drug discovery and development engine room focused on new treatments for cancer and serious disorders of the central nervous system (CNS). Through application of its proprietary technology platforms, MultiCore®, Angene® and ionX®, Bionomics has generated multiple drug candidates and targets in the therapeutic areas of Cancer, Anxiety, Multiple Sclerosis and Epilepsy. The company has a strong out-license record in conjunction with its in-house development program which has seen two highly promising drugs enter clinical trials in the past two years.